Cancer cure rate goal by 2040

Dr. Fabrice Barlesi, general director of Gustave Roussy, a cancer research center in Villejuif, has set a goal of curing 80% of cancer patients by 2040. He points out that in the 1990s, only 50% of patients were cured, and by 2026, this rate has increased to 65%, a 15-point gain in thirty years.

Technological progress and AI in cancer research

Barlesi believes it is possible to achieve another 15-point increase in the next fifteen years, driven by technological progress, improved understanding of the disease, and the expansion of therapeutic options. AI is playing a significant role in analyzing large datasets and accelerating the development of new treatments.

Evolution in cancer classification

Barlesi notes that the traditional classification of cancers by their primary location may be changing. For example, tumors with microsatellite instability, regardless of their origin, have a high chance of responding to immunotherapy. However, distinguishing between localized and metastatic disease remains important due to different treatment approaches.

AI integration in medical practices

AI is being integrated into medical practices in three levels: first, in medical imaging and tissue analysis; second, in research and analysis of large databases; and third, in designing personalized treatments using data from individual patients. This year, the first results of drugs entirely designed by AI have been observed.

Importance of cancer screening

Barlesi highlights the importance of screening in reducing cancer mortality. He notes that only 50% of women participate in breast cancer screening, and barely 30% for colon cancer. He advocates for mandatory screening, emphasizing that it can reduce mortality by 20%.

Lung cancer screening benefits

Studies involving over 150,000 people have demonstrated the benefits of lung cancer screening via scanner. In France, a study on 20,000 people is underway, but Barlesi argues that implementing widespread lung cancer screening is a matter of responsibility.

Advancements in early diagnosis

Looking ahead, Barlesi emphasizes the importance of liquid biopsy, which detects tumor DNA in the blood. This technique could enable very early diagnosis and help identify patients who no longer have detectable disease or those at risk of relapse. This would allow for more personalized treatment strategies, avoiding unnecessary treatments for some patients while intensifying care for those who need it.